Search - tctmd.com

Displaying 561 - 575 of 575

Sort: Relevancy | Date

News Daily News

ACCOAST Analysis Identifies Factors Tied to Higher Bleeding Risks in NSTE-ACS

Todd Neale

June 22, 2015

News Industry News

New Cost Effectiveness Model Underlines Scope of Polypill Strategy to Prevent Recurring Cardiovascular Events and for More Efficient Use of Health Budgets

June 19, 2015

News Industry News

Amgen Completes Enrollment In Large Cardiovascular Outcomes Trial Of Repatha™ (Evolocumab) In Patients With High Cholesterol And Clinically Evident Cardiovascular Disease

June 05, 2015

Presentation

Economic Analysis of Ticagrelor TherapyFrom a US Perspective

Presenter: Patricia A. Cowper

February 02, 2015

News Daily News

Long-term Ticagrelor Therapy Cost-Effective in US Patients

L.A. McKeown

February 02, 2015

News Daily News

与华法林或阿司匹林相比，阿哌沙班更具成本效益

Caitlin E. Cox

February 26, 2014

News Daily News

Apixaban es Rentable comparado con Warfarina o Aspirina

Caitlin E. Cox

February 26, 2014

News Daily News

Apixaban Cost-Effective Compared with Warfarin or Aspirin

Caitlin E. Cox

February 26, 2014

Presentation

Cost-Effectiveness of Apixaban vs Current Standard of Care for Stroke Prevention in A-fib Patients

Presenter: Paul Dorian

February 20, 2014

News Daily News

Apixaban Less Costly Than Aspirin for Stroke Prevention in A-Fib at 10 Years

Caitlin E. Cox

July 12, 2012

News Daily News

A los 10 Años el Apixaban resulta Más Barato que la Aspirina para la Prevención de ACV en Pacientes con FA

Caitlin E. Cox

July 12, 2012

Presentation

Cost-Effectiveness of Apixaban vs. Aspirin for Stroke Prevention Among A-fib Pts Unsuitable for Warfarin

Presenter: S. Lee

July 11, 2012

News Daily News

Selective Use of DES Saves Millions of Dollars a Year

Jason Kahn

August 15, 2011

News Daily News

Dabigatran Cost-Effective Only for A-Fib Patients at High Stroke Risk

L.A. McKeown

June 03, 2011

News Daily News

Researchers Accurately Predict Who Will Discontinue Clopidogrel

Jason Kahn

January 09, 2011

Advertisement

ACCOAST Analysis Identifies Factors Tied to Higher Bleeding Risks in NSTE-ACS

New Cost Effectiveness Model Underlines Scope of Polypill Strategy to Prevent Recurring Cardiovascular Events and for More Efficient Use of Health Budgets

Amgen Completes Enrollment In Large Cardiovascular Outcomes Trial Of Repatha™ (Evolocumab) In Patients With High Cholesterol And Clinically Evident Cardiovascular Disease

Economic Analysis of Ticagrelor TherapyFrom a US Perspective

Long-term Ticagrelor Therapy Cost-Effective in US Patients

与华法林或阿司匹林相比，阿哌沙班更具成本效益

Apixaban es Rentable comparado con Warfarina o Aspirina

Apixaban Cost-Effective Compared with Warfarin or Aspirin

Cost-Effectiveness of Apixaban vs Current Standard of Care for Stroke Prevention in A-fib Patients

Apixaban Less Costly Than Aspirin for Stroke Prevention in A-Fib at 10 Years

A los 10 Años el Apixaban resulta Más Barato que la Aspirina para la Prevención de ACV en Pacientes con FA

Cost-Effectiveness of Apixaban vs. Aspirin for Stroke Prevention Among A-fib Pts Unsuitable for Warfarin

Selective Use of DES Saves Millions of Dollars a Year

Dabigatran Cost-Effective Only for A-Fib Patients at High Stroke Risk

Researchers Accurately Predict Who Will Discontinue Clopidogrel

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content